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Inhibitors of phosphodiesterase 4 (PDE4) are potent anti-inflammatory agents, inhibiting 
the production of inflammatory mediators through the elevation of intracellular cAMP 
concentrations. We studied the activity of a novel PDE4 inhibitor, CHF6001, both in vitro 
in human cells and in vivo, using bioluminescence imaging (BLI) in mice lung inflammation. 
Mice transiently transfected with the luciferase gene under the control of an NF-κB 
responsive element (NF-κB-luc) have been used to assess the in vivo anti-inflammatory 
activity of CHF6001 in lipopolysaccharide (LPS)-induced lung inflammation. BLI as well as 
inflammatory cells and the concentrations of pro-inflammatory cytokines were monitored in 
bronchoalveolar lavage fluids (BALF) while testing in vitro its ability to affect the production 
of leukotriene B4 (LTB4), measured by LC/MS/MS, by LPS/LPS/N-formyl--methionyl--
leucyl-phenylalanine (fMLP)-activated human blood. CHF6001 inhibited the production 
of LTB4 in LPS/fMLP-activated human blood at sub-nanomolar concentrations. LPS-
induced an increase of BLI signal in NF-κB-luc mice, and CHF6001 administered by dry 
powder inhalation decreased in parallel luciferase signal, cell airway infiltration, and pro-
inflammatory cytokine concentrations in BALF. The results obtained provide in vitro and 
in vivo evidence of the anti-inflammatory activity of the potent PDE4 inhibitor CHF6001, 
showing that with a topical administration that closely mimics inhalation in humans, it 
efficiently disrupts the NF-κB activation associated with LPS challenge, an effect that may 
be relevant for the prevention of exacerbation episodes in chronic obstructive pulmonary 
disease subjects.
Keywords: LPS, inhalation towers, NF-kB, in vivo bioluminescence imaging, lung inflammation, mouse model, PDE4
BACKGROUND
Cyclic AMP (cAMP) represents a critical intracellular second messenger in immune cells such 
as macrophages (Peters-Golden, 2009) and neutrophils (Bloemen et al., 1997), where it exerts an 
inhibitory control over activation pathways leading to cytokine production and inflammation. 
Degradation of cAMP (and cGMP) into inactive products is carried out by phosphodiesterases 
Abbreviations: BLI, bioluminescence imaging; BALFs, bronchoalveolar lavage fluids; PDE4, phosphodiesterase 4; LTB4, 
leukotriene B4; LPS: lipopolysaccharide.
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(PDEs); among the different enzymes belonging to this 
superfamily, phosphodiesterase 4 (PDE4) represents the cAMP 
selective isoform mainly expressed in inflammatory and 
immune cells (Houslay, 2010). Selective inhibition of PDE4 
has been predicted to have potential anti-inflammatory activity 
in lung inflammatory pathologies, such as asthma and chronic 
obstructive pulmonary disease (COPD), but early on inhaled 
corticosteroids (ICS) become the anti-inflammatory of choice in 
asthma, while the use of oral PDE4 inhibitors was complicated 
by variable activity and the presence of significant side effects, 
in particular gastrointestinal. In light of these limitations, only 
one oral PDE4 inhibitor (namely roflumilast) is at present 
commercially available for use in COPD (Giembycz and Field, 
2010), a pathology where at variance with asthma, ICS cannot 
effectively control airway phlogosis.
CHF6001 is a PDE4 inhibitor optimized for inhaled delivery 
with the goal of achieving maximal efficacy in airways while 
reducing systemic exposure and side effects (Moretto et al., 
2015; Villetti et al., 2015). When administered by dry powder 
inhalation, CHF6001 is well tolerated up to 4,800 µg in humans 
(Mariotti et al., 2018) and is currently in phase IIb clinical trials 
for the treatment of COPD (clinicaltrials.gov).
LTB4 is a potent chemoattractant and activator of leukocytes 
that significantly enhances neutrophil adhesion to endothelial 
cells (Hoover et al., 1984), promoting neutrophil infiltration 
into inflamed tissues (Kim et al., 2006). Its synthesis relies on 
the availability of arachidonic acid released from membrane 
phospholipids by the cytosolic phospholipase A2 (cPLA2), as 
cPLA2-null mice cannot produce LTB4 (Bonventre et al., 1997). 
LTB4, like other chemoattractants, inhibits activated adenylyl 
cyclase activity through Gi-like G-proteins and enhances the 
activity of nuclear factor kappaB (NF-κB) (Sanchez-Galan et al., 
2009; Serezani et al., 2011).
NF-κB is a redox-sensitive transcription factor that plays a 
critical role in a wide array of inflammatory networks regulating 
cytokine production in airway pathologies, including COPD 
(Schuliga, 2015). NF-κB activation in pulmonary inflammation is 
mainly induced by mediators such as interleukin (IL)-1β, tumor 
necrosis factor (TNF)-α, or by bacterial or viral exacerbations 
activating Toll-like receptors (Edwards et al., 2009). NF-κB may 
also be involved in the control of five-lipoxygenase activating 
protein (FLAP, a key protein for leukotriene synthesis in intact 
cells) expression and may therefore increase LTB4 production in 
a vicious positive feedback cycle (Gonsalves and Kalra, 2010). 
Modulation of NF-κB activation using both small molecules, 
decoy oligonucleotides, or siRNA has been successful in animal 
models, but transition to humans still requires the identification 
of specific targets and the development of active inhibitors 
(Rahman and Fazal, 2011).
In the present study, we evaluated the anti-inflammatory 
activity of CHF6001 both in vitro and in vivo, assessing the 
ability to inhibit the production of the potent neutrophil 
chemotactic factor LTB4 in lipopolysaccharide (LPS)/N-
formyl--methionyl--leucyl-phenylalanine (fMLP)-activated 
human blood and the effects on the pulmonary inflammatory 
response, resulting from LPS intratracheal challenge. We 
assessed the anti-inflammatory activity in vivo administering 
the dry powder developed for clinical use through an 
inhalation tower by enabling the testing in animals of the 
same formulation administered to patients and monitored 
pulmonary inflammation with the noninvasive assessment 
of NF-κB activation in mice transiently transfected with the 
luciferase gene under the control of NF-κB responsive element.
The results obtained with CHF6001 showed a potent inhibition 
of critical components of the inflammatory response elicited by 
LPS, especially in vivo upon a topical administration that closely 
mimics inhalation in humans and supports a significant anti-
inflammatory activity by CHF6001 that may be fully exploited 
for the prevention of exacerbation episodes in COPD subjects.
METHODS
Animals
Female FVB (7–8 weeks old) mice were purchased from Harlan 
Laboratories Italy (S. Pietro al Natisone, Udine, Italy).
In this study, only female mice were used since male rats and 
mice were used to evaluate the anti-inflammatory activity of 
CHF6001 in a study we published previously (Villetti et al., 2015) 
and we do not expect any difference in LPS challenge between 
the male and female.
Animals were maintained under conventional housing 
conditions. Prior to use, animals were acclimated for at least 5 days 
to the local vivarium conditions (room temperature: 20–24°C; 
relative humidity: 40–70%), having free access to standard rat 
chow and tap water. All animal experiments described herein 
were approved by the intramural animal welfare committee for 
animal experimentation of Chiesi Farmaceutici under protocol 
number 0013415-P-25/07/2011 which comply with the European 
Directive 2010/63 UE, Italian D.Lgs 26/2014, and the revised 
“Guide for the Care and Use of Laboratory Animals” (Guide for 
the Care and Use of Laboratory Animals, 1996).
Reagents
LPS (from Escherichia coli 0111:B4, product n.L3012) was from 
Sigma (St. Louis, MO); JetPEI was from Polyplustransfection 
Inc (Euroclone, Milano, Italy); NF-κB vector (pGL4.32[luc2P/
NF-jB-RE/Hygro]) was from Promega (Madison, WI); CHF6001 
(M.W. 687.54) was synthesized at Chiesi Farmaceutici S.p.A., 
Parma, Italy (Armani et al., 2014). Lactose (Inhalac, containing 
magnesium stearate only) was used as vehicle, and micronized 
CHF6001 blend and vehicle were compressed into the canister 
using a hydraulic press. [d4]LTB4 and LTB4 were from Cayman 
Chem. (Ann Arbor, MI).
LTB4 Production in Human Whole Blood
LTB4 production was elicited in human blood cells according 
to Brideau et al. (1999), with modifications. Briefly, human 
“buffy coat” (Blood Bank, University of Milan) diluted 1:4 with 
homologous plasma and 10 UI/ml heparin was treated with LPS 
(1 µg/ml) at 37°C with or without CHF6001 (0.1 pM–1 µM), the 
FLAP inhibitor MK886 (1 µM), the selective COX2 inhibitor 
lumiracoxib (30 nM), or the non-selective COX1–COX2 
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inhibitor indomethacin (30 µM). After 24 h, samples were added 
with LPS again for 30 min followed by the formylated tripeptide 
fMLP (1 µM) for additional 15 min at 37°C. Supernatants from 
rapid centrifugation at 13,000 × g for 3 min, 4°C were recovered, 
added with three volumes of acetonitrile containing [d4]LTB4, 
and maintained at −20°C until analysis.
Each treatment had two replicates with cells from the same 
donor and concentration–response curves were originated using 
the average values from at least three different donors.
LTB4 Analysis by LC/MS/MS Mass 
Spectrometry
Supernatants from blood incubations, containing the deuterated 
internal standard for the stable isotope dilution quantitative 
determination, were centrifuged at 13,000 × g for 5 min, 4°C 
to precipitate proteins and, upon dilution with two volumes 
of solvent A (ammonium acetate buffer, pH 5.7), analyzed by 
LC/MS/MS using selected reaction monitoring of the specific 
transitions from m/z 335 to 195 (LTB4) and m/z 339 to 197 ([d4]
LTB4) as previously described (Zarini et al., 2009).
Quantitation was obtained using standard curves of 
synthetic LTB4.
Vector Characteristic and In Vivo  
Gene Delivery
The pGL4.32[luc2P/NF-jB-RE/Hygro] vector (GenBank/EMBL 
accession number EU581860) contains five copies of an NF-κB 
responsive element (NF-κB-RE) that drives transcription of the 
luciferase reporter gene luc2P (Photinus pyralis). Multimerization 
of responsive elements is frequently used to increase the sensitivity 
to a specific transcription factor. In this case, five copies of NF-kB 
have been considered a good compromise to increase sensitivity 
and maintain physiological conditions. Higher copy numbers 
of a NF-kB responsive element could lead to recruit unspecific 
transcription factors, dysregulating the promoter activation.
Luc2P is a synthetically derived luciferase sequence with 
humanized codon optimization that is designed for high 
expression and reduced anomalous transcription. The luc2P 
gene contains hPEST, a protein destabilization sequence. The 
protein encoded by luc2P responds more quickly than the 
protein encoded by the luc2 gene upon induction. The vector 
backbone contains a resistance gene to allow selection in E. coli 
and a mammalian selectable marker for hygromycin resistance. 
JetPEI (Wu et al., 2004; Oh et al., 2013) was applied in vivo as a 
carrier for delivering DNA to lung tissues. The DNA and JetPEI 
were formulated according to the product manual. Briefly, 40 µg 
of NF-κB-luc reporter and 7 µl of JetPEI were each diluted into 
100 µl of 5% glucose. The two solutions were then mixed and 
incubated for 15 min at room temperature. The entire mixture 
(approximately 200 µl) was injected into the tail vein of mice. Both 
DNA and JetPEI are toxic if injected at high doses, and therefore 
a careful optimization of the transfection conditions also in terms 
of DNA and JetPEI relative ratio has been performed to obtain 
the desired lung transfection efficiency and avoid or minimize 
in vivo toxicity. The intravenous route of administration has 
been selected based on our preview studies showing that upon 
intravenous injection, in vivo JetPEI-mediated DNA delivery 
leads to gene expression mainly in the lung ((Stellari et al., 2012; 
Stellari et al., 2014a; Stellari et al., 2015a; Stellari et al., 2017).
The optimized transfection protocol, as described, has been 
applied also in this study, and, following LPS challenge, we have 
observed a fold induction of bioluminescence in lung tissue 
comparable with our previous studies. Suggestions regarding 
different ways of administration and protocol for in vivo gene 
delivery have been proposed by PolyPLus (https://www.polyplus-
transfection.com).
In Vivo Bioluminescence Imaging
Bioluminescence imaging (BLI) is a noninvasive method, and 
therefore the 3R rule is intrinsic to its nature.
As previously reported (Stellari et al., 2014b), transfection 
per se causes a mild lung inflammatory response and NF-κB 
activation that is detectable by BLI up to 3–4 days after DNA 
injection and disappears completely after 1 week. Therefore, 
1 week after DNA delivery, the transient transgenic mice 
were injected with luciferin i.p. and BLI was recorded. Briefly, 
following intraperitoneal injection of luciferin (150 mg/kg), 
mice were lightly anesthetized with isoflurane (2.5%) and images 
were obtained using an IVIS imaging system (PerkinElmer, 
Inc., Waltham, MA) at 10 and 15 min after luciferin: an average 
of photons emitted from the chest of the mice was quantified 
using Living ImageJ software (PerkinElmer, Inc., Waltham, 
MA). The following day, mice were intratracheally challenged 
with LPS (12.5 µg/mouse) and BLI was recorded at 2, 4, 7, and 
24 h after LPS instillation, 15 min after i.p. injection of luciferin 
(150 mg/kg).
Acute Pulmonary Inflammation: Effect  
of CHF6001
Intratracheal (i.tr.) challenge with LPS was carried out using 50 
µl of LPS solution [250 µg/ml in phosphate-buffered solution 
(PBS)] and a 22-gauge intubator, resulting in a final dose of 
LPS of 12.5 µg/mouse, with the control group receiving 50 µl of 
saline i.tr.
The mice were treated by the snout-only inhalation route as 
a 15-min exposure. Test groups were exposed to an atmosphere 
containing CHF6001 (supplied as a nominal 4% (w/w) blend 
in vehicle). Different doses were achieved by varying the 
concentration of the CHF6001 in the tower. The control group 
animals were exposed to the vehicle.
At least one sample was collected from each exposure system.
Concentration samples used an open-face filter and particle 
size analysis was carried out using a Marple (model 296) Personal 
Cascade Impactor with stainless steel collection substrates and a 
glass fiber filter. Samples were collected from each test group. The 
mass median aerodynamic diameter (MMAD) and geometric 
standard deviation of the aerosol were derived for each occasion 
of measurement.
Collected samples were retained for analysis of CHF6001 by 
LC/MS/MS (Villetti et al., 2015).
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Broncho-Alveolar Lavage Fluid Analysis
Bronchoalveolar lavage (BAL) fluid collection was performed 
24 h after LPS challenge. Mice were sacrificed by an overdose 
of isoflurane and a midline neck incision was performed to 
cannulate the trachea. Lungs were washed three times with 0.6 
ml of PBS as previously described (Nassini et al., 2012). Cell 
counts were performed with an automated cell counter (Sysmex 
XT100V, Dasit).
For flow cytometric analysis, cells were labeled in PBS 
(Euroclone) and 0.5% bovine serum albumin (BSA, Milteny 
Biotech) with fluorochrome-labeled monoclonal antibodies: 
anti-mouse CD 45 PE-Cy5 (BD Pharmigen), anti-mouse F4/80 
Alexa 488 (AbD Serotec), anti-mouse Lys6G (BD Pharmigen), 
anti-mouse CD11b PE-Cy7 (BD Pharmigen), and appropriate 
isotype controls for 30 min at RT in the dark. Cells were washed 
before and after the staining and resuspended in 300 µl of PBS/
BSA. Samples were collected on a FACS Canto II (two lasers, six 
colors, Becton Dickinson) and analyzed using Diva 7 software. 
Mean fluorescence intensity (MFI) was determined on a 
statistically significant number of cells each sample. To positively 
select all leukocytes in BAL and discard debris, gating was 
performed on CD45-positive cells. Anti-mouse F4/80 was used 
to discriminate granulocyte population, including eosinophils 
and neutrophils, from macrophages. Lymphocytes were gated out 
based on forward scatter (FSC) and side scatter (SSC). Moreover, 
anti-mouse GR1+ was used to negatively gate out all neutrophils. 
Fluorescence-activated cell sorting (FACS) analysis finally 
quantitated CD11b surface activation marker expression on the 
remaining population of monocytes/macrophages characterized 
as CD45+ F4/80+ GR1− cells.
Cytokine and chemokine levels were measured in the 
bronchoalveolar lavage fluid (BALF) supernatants using a Bio-
Plex™ Cytokine Assay Kit (Bio-Rad Laboratories, Segrate, Milano, 
Italy) according to the manufacturer’s instructions as previously 
published (Stellari et al., 2014b; Stellari et al., 2015a).
Statistical Analysis
As tests for normality were positive, statistical analysis was 
performed on raw data using one-way analysis of variance 
(ANOVA) followed by Dunnett’s t post hoc test for comparison 
with control groups. Experimental values were expressed 
as the mean and standard error of the mean (SEM) of n 
observations. (*P < 0.05, **P < 0.01, ***P < 0.001). Sigmoidal 
dose–response curve was obtained and IC50 calculated using 
GraphPad Prism 4.00. 
RESULTS
Effect of CHF6001on LTB4 Production by 
LPS-Activated Human Blood Cells
The 24-h incubation with the bacterial membranes LPS followed 
by LPS and fMLP activation resulted in a significant production 
of LTB4, in agreement with previous reports (Brideau et al., 1999). 
Synthesis of LTB4 was completely prevented in the presence of 
the leukotriene synthesis inhibitor MK886 (1 µM), a compound 
preventing docking of 5-lipoxygenase to the nuclear membrane 
(Dixon et al., 1990) and access to the substrate arachidonic acid 
released by phospholipase A2 (Abramovitz et al., 1993), but was 
unaffected by either the specific COX-2 inhibitor lumiracoxib or 
the nonspecific COX1–COX2 inhibitor indomethacin (Figure 1A). 
CHF6001 concentration-dependently prevented the formation of 
FIGURE 1 | LTB4 inhibition by CHF6001. (A) Human blood was treated with 
LPS (1 µg/ml) in the presence or absence of different compounds, followed 
by lipopolysaccharide (LPS) again after 24 h and the formylated tripeptide 
N-formyl--methionyl--leucyl-phenylalanine (fMLP, 1 µM) as described in 
METHODS. LTB4 production was assessed by LC/MS/MS using stable 
isotope dilution. (B) Concentration–response curve of the inhibitory effect 
of CHF6001 on LTB4 production by LPS/LPS/fMLP activated human 
blood, assessed by LC/MS/MS using stable isotope dilution. Values are 
shown as the mean ± SEM, n = 4 for each group. ***P < 0.001 versus LPS 
group (Dunnett’s test). Sigmoidal dose–response curve was obtained using 
GraphPad Prism 4.00.
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the potent neutrophilic chemotactic factor LTB4 with an IC50 of 
79 pM (Figure 1B), but was ineffective against direct activation of 
5-LO by the calcium ionophore A23187 (data not shown).
Inhaled Dose of CHF6001
Monitoring aerosol concentrations of CHF6001 dry powder 
delivered within the airways of the experimental animals using 
the snout-only delivery tower (Figure 2) resulted in an estimated 
dose inhaled close to target at all three doses used and showed 
good inter-experiment reproducibility (Table 1 and Table 2).
Effect of CHF6001 on Acute Pulmonary 
Inflammation in Mice
As previously reported (Ansaldi et al., 2011; Stellari et al., 
2014b; Stellari et al., 2015b), LPS intratracheal instillation 1 
week after DNA delivery of the luciferase reporter construct 
caused the activation of NF-kB in the lungs, which could be 
easily monitored by BLI showing a very marked increase when 
compared to control animals. Luciferase expression driven 
by NF-kB activation was detectable by BLI as early as 2 h after 
LPS challenge and peaked at 4 h after treatment, with a fivefold 
induction over baseline (Figures 3A and B). The signal was still 
significantly enhanced 7 h after LPS, but returned to baseline 
levels 24 h after LPS challenge (data not shown).
Pretreatment with CHF6001 by Inhalation using the snout-
only delivery tower, closely mimicking inhalation in humans, 
dose-dependently reduced the BLI Signal (Figure 3A). 
quantitative determination of bli in the transient transgenic mice 
showed a maximal inhibition of the increase in BLI caused by 
LPS of ≈50% (Figure 3B).
FIGURE 2 | A schematic of the Chiesi inhalation towers. (A) Wrights Dust Feed. (B) Pre-chamber. (C) Tangential air inlet. (D) Viewing port in top section. (E) Restraint 
tube attached to the tower. (F) Vacant animal ports closed off with bungs. (G) Conical exhaust plenum. (H) Aerosol monitoring device. (I) Filtration units in extract.
TABLE 1 | Estimated inhaled doses (mg/kg) of CHF6001.
Target dose 
(mg/kg)
Estimated inhaled dose 
(mean of 2 doses)
% of Target
0.1 0.0856 85.6
0.3 0.290 96.7
0.6 0.664 111
0.6 repeat 0.631 105
The inhaled dose was derived using the following equation [43]:
Delivered dose( g/ kg)µ =
Conc RMV D
BW
x x
Where Conc., concentration of CHF6001 in air inhaled (µg/l).
RMV, volume of air inhaled in 1 min (l/min) 0.608 x BW (kg)0.852.
D, duration of exposure to the aerosol (min).
BW, body weight (kg).
TABLE 2 | Mass median aerodynamic diameter (MMAD, µm) of CHF6001.
CHF6001 dose (mg/kg) MMAD (µm) σg
0.1 1.7 2.19
0.3 1.9 2.25
0.6 2.1 2.23
MMAD, Mass median aerodynamic diameter.
σg, Geometric standard deviation.
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The numbers of white blood cells (WBC) and neutrophils 
recovered by BAL 24 h after LPS challenge increased by over 
20-/40-fold when compared to vehicle-treated animals, and this 
increase was also dose-dependently inhibited with CHF6001 
inhalation pretreatment by 41%/38% (Figures 4A and B). A 
highly statistically significant correlation was observed between 
BLI quantified 4 h after LPS administration and the number of 
WBC and neutrophils recovered by BAL 24 h after LPS challenge 
(Figure 4C), strongly supporting the presence of a quantitative 
correlation between NF-kB activation, BLI determination, and 
the immune response represented by white blood cell infiltration 
of the lung airways. The marked inhibition of BLI/WBC 
infiltration confirmed the potent pulmonary anti-inflammatory 
activity of the compound administered by inhalation.
LPS-driven NF-kB activation also contributes to neutrophil 
extravasation and infiltration by inducing the expression of 
adhesion molecules (Zhou et al., 2005), and CD11b expression 
analysis by FACS on neutrophils recovered in BAL reported 
a very marked increase following LPS challenge, an increase 
that was also dose-dependently affected by pretreatment with 
CHF6001 (Figure 4D).
In a similar fashion, LPS-induced increase in BAL 
concentrations of several pro-inflammatory cytokines, such 
as TNF-α, granulocyte colony-stimulating factor (G-CSF), 
interleukin 1β (IL-1β), and regulated on activation, normal T 
cell expressed and secreted (RANTES) (Figures 5A–D), was 
markedly inhibited by CHF6001, underscoring its effective anti-
inflammatory activity.
DISCUSSION
Increase in airway inflammation is a critical feature of exacerbations 
in COPD subjects and patients with frequent exacerbations are 
showing increased mortality rates (Soler-Cataluña et al., 2005). 
FIGURE 3 | Effects of CHF6001 on NF-kB activation in vivo as assessed by bioluminescence imaging (BLI). (A) Transient NF-kB-luc transgenic mice were 
pretreated with saline or CHF6001 (100–600 µg/kg by inhalation) 1 h before lipopolysaccharide (LPS) intratracheal instillation. Representative mice are shown for 
saline, LPS, LPS+CHF6001 (100 µg/kg), and LPS+CHF6001 (600 µg/kg). (B) Quantification of NF-kB activation by BLI, 4 h after LPS intratracheal instillation. Values 
are shown as the mean ± SEM, n = 6, and percent inhibition versus LPS group is reported. **P < 0.01 versus LPS group (Dunnett’s test).
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Several factors such as infections, increased oxidative stress, and 
altered immunological response may be the cause of such a rise 
in inflammation during exacerbations. In particular, bacterial 
infections account for a significant fraction of all exacerbations 
(White et al., 2003) and have been reported to cause increased 
airway inflammation; biomarkers of inflammation such as MPO, 
neutrophil elastase activity, IL-8, and LTB4 levels all are positively 
related to sputum bacterial load in fresh sputum samples from 
COPD patients (Hill et al., 2000). At the same time, NF-kB 
activation has been reported in inflammatory cells within 
the airways of COPD subjects during COPD exacerbations 
(Caramori et al., 2003; Drost et al., 2005), suggesting a potential 
role for this transcription factor in the inflammatory burst 
associated with exacerbations.
In the present paper, we describe the potent anti-inflammatory 
activity of a novel inhaled PDE4 inhibitor that may represent a 
step forward in the prevention and management of acute events 
in COPD patients. CHF6001 has been developed (currently 
in phase IIb clinical trials, see clinicaltrials.gov) as a new drug 
specifically designed for inhalation delivery (Moretto et al., 
2015), with the goal of limiting systemic exposure and avoid the 
serious, dose-limiting side effects of oral PDE4 inhibitors such 
as roflumilast (Page and Spina, 2011; Gupta, 2012; ). In order 
to closely mimic the inhalatory route of administration used 
in humans, we used the dry powder developed for clinical use, 
delivering it through snout-only inhalation towers.
The ability of CHF6001 to suppress LTB4 formation by 
human blood in vitro, without directly affecting 5-lipoxygenase, 
suggests that the inhibition of PDE4 at sub-nanomolar 
concentrations can effectively lower the overall inflammatory 
response of blood leukocytes to the immunological stimulus 
represented by bacterial wall lipopolysaccharides. LTB4 has 
FIGURE 4 | Effects of CHF6001 on lipopolysaccharide (LPS)-induced neutrophils and white blood cell (WBC) recruitment and on monocyte/macrophages adhesion 
molecule expression. (A) and (B) Transient NF-kBluc transgenic mice were pretreated with saline or CHF6001 (100–600 µg/kg) 1 h before LPS and sacrificed 24 h 
after LPS administration by tracheal instillation. WBC (A) and neutrophils (B) were counted with an automated cell counter. (C) Correlation between NF-kB activation 
as measured by BLI, 4 h after LPS instillation, and the concentrations of WBC in bronchoalveolar lavage fluids, obtained 24 h after LPS instillation. (D) CD11b 
surface activation marker expression on monocytes/macrophages characterized as CD45+ F4/80+ GR1− cells. Values are shown as the mean ± SEM, n = 6 for each 
group, and percent inhibition versus LPS group is reported. *P < 0.05, **P < 0.01 versus LPS group (Dunnett’s test).
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been reported, together with IL-8, among the chemoattractants 
involved in the recruitment of neutrophils in the airways, 
and its concentrations are increased in induced sputum from 
COPD subjects (Profita et al., 2005) and further increase during 
exacerbations (Biernacki et al., 2003).
The potent in vitro inhibition of cytokine and chemokine 
production from LPS-activated peripheral blood mononuclear 
cells and macrophages caused by CHF6001 (Moretto et al., 
2015) was confirmed in vivo in a widely used model of airway 
acute inflammatory response elicited by the local instillation 
of bacterial LPS in mice. Preclinical models of COPD are often 
of limited relevance for the pathology in humans; however, 
monitoring the inflammatory response using a NF-kB activation 
reporter gene in a transient transgenic mouse allowed to follow a 
specific molecular event that plays a critical role at the crossroad 
of multiple inflammatory triggers.
The inhalation route is increasingly adopted to deliver local or 
systemic therapeutics, and rodent models used in development 
and tolerability studies should mimic as closely as possible the 
intended formulation and delivery methods. Tracheal intubation 
with insufflation of metered dry powders has been used to 
deliver directly into the lungs, but the method requires invasive 
surgery, extensive skills, and has been characterized as resulting 
in irreproducible dosage delivery, lung damages, and respiratory 
failure in significant numbers of animals (Diot et al., 2012). In 
order to fill as much as possible the gap between preclinical 
models and the real life of human administrations, we used 
inhalation towers to treat mice with a dry powder formulation 
of CHF6001 used in clinical trials. Inhaled administration of 
CHF6001 significantly and dose-dependently turned off NF-kB-
dependent luciferase activity in LPS-challenged mice and the 
ability to monitor NF-kB activation noninvasively by BLI is 
FIGURE 5 | Effects of CHF6001 on cytokine concentrations in bronchoalveolar lavage fluids. Transient NF-kB-luc transgenic mice were pretreated with saline or 
CHF6001 (100–600 µg/kg) 1 h prior to lipopolysaccharide (LPS) and sacrificed 24 h after tracheal instillation of LPS. Cytokines were assessed using a Bio-Plex™ 
Cytokine Assay Kit as described in METHODS. (A) Tumor necrosis factor alpha (TNF-α). (B) Granulocyte colony-stimulating factor (G-CSF). (C) Regulated on 
activation, normal T cell expressed and secreted (RANTES). (D) IL-1β. Values are shown as the mean ± SEM, n = 6 for each group. *P < 0.05, **P <0.01 versus LPS 
group (Dunnett’s test).
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pertinent to the 3R rule. Screening all mice for the basal level 
of NF-kb activation before entering the experimental protocol, 
and using each mouse as its own control, greatly limited the 
variability and allowed the use of a reduced number of animals.
When compared to LPS-challenged, non-treated animals, 
the inhibition of LPS-induced NF-kB activation by CHF6001 
resulted associated to a significant suppression of lung cellular 
infiltrates as well as of the concentrations of NF-kB-activating 
inflammatory cytokines such as IL-1β and TNF-α in BAL at 24 h 
after challenge.
Expression of endothelial adhesion molecules facilitating 
cell migration as well as activation of monocyte–macrophages 
may result from production of TNF-α, which is known to be 
increased in sputum during exacerbations (White et al., 2003). 
The inhibition on the expression of adhesion molecules by FACS 
analysis upon CHF6001 topical treatment, together with the 
decreased number of infiltrating WBC, is also in line with the 
observed decrease of TNF-α in BALF concentrations.
Recent evidence in knockout mice suggests that G-CSF may 
play a previously unreported, relevant pathogenic role in COPD 
(Tsantikos et al., 2018); CHF6001 marked inhibition of G-CSF 
production may therefore contribute to the overall control of the 
inflammatory response elicited by bacterial lipopolysaccharides 
in our model as well as during infection-driven exacerbations in 
COPD subjects.
The overall ability of inhaled CHF6001 to hamper the 
production of a number of relevant pro-inflammatory mediators, 
including RANTES and IL-1β, suggests that this compound may 
represent a significant step forward in the search for an improved 
control of acute airway inflammation associated with bacterial 
infections in COPD. Taken together, these results bode well for 
the development of much needed therapeutics for the treatment 
of COPD. The combination of an advanced delivery route and 
in vivo imaging techniques can therefore be used in support of 
undergoing clinical trials to either identify biomarkers that can 
be used (activation of NF-kB, production of LTB4, TNF-β, G-CSF, 
etc.) or direct the enrolment of patients with specific phenotypes 
(such as subjects with a high bacterial load, given the observed 
efficacy in modulating the inflammatory reaction associated to 
the exposure to a component of Gram-negative bacterial wall).
CONCLUSIONS
The results of this study provide evidence of a potent in vitro 
and in vivo anti-inflammatory activity associated with PDE4 
inhibition, as shown by inhibition of LTB4 production induced by 
LPS in human blood and by the suppression of NF-kB activation 
with the associated production of inflammatory cytokines in 
mice topically treated using an inhalation system that closely 
mimics the administration of dry powders in humans.
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